Page last updated: 2024-12-07
4,4'-azobis(phenol)
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4'-azobis(phenol): isolated from fungus Agaricus xanthodermus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 101245 |
CHEMBL ID | 116175 |
SCHEMBL ID | 901189 |
MeSH ID | M0131146 |
Synonyms (48)
Synonym |
---|
4,4-dihydroxyazobenzene |
nsc-402595 |
2050-16-0 |
nsc402595 |
CHEMBL116175 |
AKOS003619052 |
4-[(4-hydroxyphenyl)hydrazinylidene]cyclohexa-2,5-dien-1-one |
4,4'-azobis(phenol) |
nsc 402595 |
phenol, 4,4'-azobis- |
ai3-08894 |
4,4'-dihydroxyazobenzene |
4-[(4-hydroxyphenyl)diazenyl]phenol |
phenol,4,4'-(1,2-diazenediyl)bis- |
4-(4-hydroxyphenylazo)phenol |
trans-4,4'-azodiphenol |
unii-f4ylc7i7dn |
phenol, 4,4'-(1,2-diazenediyl)bis- |
p-azophenol |
phenol, 4,4'-azodi |
4,4'-azodiphenol |
51437-66-2 |
phenol, 4,4'-(1e)-1,2-diazenediylbis- |
f4ylc7i7dn , |
p,p'-dihydroxyazobenzene |
SCHEMBL901189 |
WKODVHZBYIBMOC-UHFFFAOYSA-N |
WKODVHZBYIBMOC-BUHFOSPRSA-N |
di-(4-hydroxy-phenyl)-diazene |
D3431 |
AKOS028112956 |
mfcd00045778 |
SY056471 |
4,4 inverted exclamation mark -dihydroxyazobenzene |
(e)-4,4-(diazene-1,2-diyl)diphenol pound ws201781 pound(c) |
E72619 |
AS-18987 |
10.14272/WKODVHZBYIBMOC-BUHFOSPRSA-N |
doi:10.14272/wkodvhzbyibmoc-buhfosprsa-n.1 |
(e)-4,4'-(diazene-1,2-diyl)diphenol |
N10032 |
Q27277636 |
A910719 |
YSWG059 |
4,4-(diazene-1,2-diyl)diphenol |
CAA05016 |
4,4'-(e)-diazene-1,2-diyldiphenol |
CS-W018449 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1127148 | Binding affinity to ERalpha (unknown origin) relative to estradiol | 2014 | Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8 | Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor. |
AID481675 | Induction of human ApoA-1 gene expression in human Caco-2 cells co-transfected with luc-beta-galactosidase after 48 hrs assessed as luciferase activity by luminometer relative to resveratrol | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Stilbene analogs as inducers of apolipoprotein-I transcription. |
AID481674 | Induction of human ApoA-1 gene expression in human Caco-2 cells co-transfected with luc-beta-galactosidase after 48 hrs assessed as luciferase activity by luminometer relative to control | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Stilbene analogs as inducers of apolipoprotein-I transcription. |
AID216186 | The compound was tested for antiviral activity against Herpes simplex virus type-1 in the vero cells using plaque inhibition assay; no IC50 reached without damage to the cell monolayer. | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17 | Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |